Figure 1: Proposed model structure for Non-Neuropathic Chronic Pain
Though the care pathway for chronic pain may be complex and heterogeneous, data limitations may preclude meaningful benefit from discrete event or discrete individual simulation approaches, and the proposed model is a Markov state-transition model. The model depicted in Figure 1 is designed with the flexibility to test the sensitivity of model outcomes to the inclusion/exclusion of 3rd-line treatment options and adjustments to costs and outcomes in initial treatment weeks attributable to dose titration.
This systematic search and methodological review of chronic pain models has highlighted variability across studies in terms of assumptions about treatment choice and effectiveness at subsequent treatment lines. Heterogeneity also exists concerning model type, choice of time horizon and consideration of dose titration and treatment-emergent adverse effects. Further research is required to test the strengths, weaknesses and consequences of key modelling choices.
A systematic search and methodological review of published economic models of therapies in chronic pain was performed. MEDLINE, EMBASE, Health Technology Assessment, NHS Economic Evaluation Database and EconLit were accessed in April 2014. Key methodological data were extracted from included studies and analysed.
Published full economic evaluations using economic models were included whilst partial economic evaluations, economic evaluations which have not used modelling assumptions, cost-of-illness studies, commentary-type studies and unpublished work were excluded. The scope of the review was limited to economic evaluations in neuropathic pain or for which the broad pathway of chronic pain treatment drove the modelling approach. Studies that model the nuances of a particular disease exhibit methodological heterogeneity. For this reason, though the search strategy was broad, studies specific to osteoarthritis, low back pain, fibromyalgia and post-surgery pain were excluded from the final review. Studies published before the year 2000 or where an English language version could not be retrieved were also excluded.
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Methods
Objectives
There is unmet need in patients suffering from chronic pain (Breivik et al, 2013) . Despite this, innovation may be impeded by the difficulty of justifying economic value in a field beset by data limitations and methodological variability. These problems may also be affecting the ability of decision makers to make correct resource allocation decisions. A systematic review was conducted to identify and summarise the key areas of variability and limitations in modelling approaches for economic evaluations of treatments for chronic pain.
By summarising existing published economic models and identifying key model characteristics, it was possible to frame and propose a flexible model structure for a de novo model to explore key areas of uncertainty. Overall, this research aims to facilitate increased consensus for future development of pain models.
Thirty-four studies were included in the final review. From these, 18 original model structures were identified. Key characteristics of these models are summarised in Table 1. Chronic non-neuropathic pain modelling studies in the review have exclusively evaluated opioid-based treatments, including regimens of tapentadol, tramadol, oxycodone, fentanyl, buprenorphine and oxycodone/naloxone. For neuropathic pain, treatments modelled have also included opioids, but principally focus on antiepileptic drugs, tricyclic antidepressants, selective serotonin reuptake inhibitors and topical creams. This has justifiably driven differences in modelling approaches between neuropathic pain and other chronic pain studies, though further differences between studies within these disease sub-types are evident from Table 1 and may not be necessary or desirable.
No studies presented data from trials of consecutive treatment lines for chronic pain patients. Nevertheless, as shown in Table 1 , multiple treatment lines were considered in 11 model structures. In these studies, various assumptions were made about treatment choice and effectiveness at subsequent treatment lines. Only three models used a time horizon of greater than 1 year. Explicit consideration of adverse events was common in neuropathic pain models (14 of 16) and characteristic of all chronic pain models. Titration was considered by three of eight non-neuropathic pain models, but only two of 10 neuropathic pain models. The majority of models (11) used a Markov structure, but four of 10 neuropathic pain models used decision trees. 
Future Research
Planned research will test the importance of key structural and data modelling assumptions for non-neuropathic chronic pain model outcomes, using the model structure shown in Figure 1 . The model will be made freely available to the research community in an effort to promote consistency and transparency and ultimately improve resource allocation decisions for chronic pain treatment. 
Discussion / Conclusions
Exploration of the importance of key modelling assumptions for model outcomes in economic models of neuropathic and other chronic pain is warranted. To explore the implications of key modelling assumptions for economic evaluations of oral treatments for non-neuropathic chronic pain, and help guide aligned future practice, we have designed a flexible model structure, shown in Figure 1 .
AEs, adverse events.
